This review revisits the role of growth hormone (GH) in heart failure (HF), highlighting its potential therapeutic benefits due to its anabolic, vasodilatory, and anti-apoptotic properties. Early studies suggested improvements in cardiovascular parameters with GH therapy; however, larger trials yielded inconsistent results. The authors discuss the concept of multiple hormonal
This comprehensive analysis reviewed data from multiple growth hormone (GH) registries to assess the long-term safety of GH treatment in children and adults. The study found no increased risk of mortality, stroke, or new malignancies in GH-treated individuals without pre-existing risk factors. However, an elevated risk of secondary neoplasms was
This randomized, double-blind, placebo-controlled trial assessed the effects of the oral ghrelin mimetic MK-677 (25 mg daily) on growth hormone (GH) secretion, body composition, and clinical outcomes in 65 healthy adults aged 60–81 over 12 months. MK-677 significantly increased 24-hour mean GH and insulin-like growth factor I (IGF-I) levels to
The TRIIM (Thymus Regeneration, Immunorestoration, and Insulin Mitigation) trial examined the effects of a one-year intervention using recombinant human growth hormone (rhGH), dehydroepiandrosterone (DHEA), and metformin on epigenetic aging and immune system function in nine healthy men aged 51–65. The study demonstrated a significant reversal in biological age by an
This review examines the complex role of growth hormone (GH) in mammalian aging. While GH levels decline with age, this reduction may serve as a protective mechanism against age-related diseases, including cancer. Animal studies demonstrate that absence of GH signaling can extend lifespan, suggesting a deceleration of aging processes. In
This review evaluates the effects of growth hormone (GH) supplementation in aging men, noting that GH and IGF-1 levels decline with age, leading to changes in body composition and function. Controlled studies indicate that GH therapy modestly increases lean body mass by approximately 2 kg and reduces fat mass similarly.
This review explores the controversial role of growth hormone (GH) in aging. While GH levels naturally decline with age and GH therapy has been proposed for anti-aging, evidence suggests reduced GH/IGF-1 activity is associated with increased lifespan and decreased cancer risk in animal models. Human studies on GH therapy in
This review explores the role of various hormone therapies in managing congestive heart failure (CHF). It highlights the significance of neurohormonal systems in CHF pathophysiology and discusses treatments like the dual-acting drug valsartan/sacubitril, which shows promise alongside traditional medications such as beta-blockers, ACE inhibitors, ARBs, and mineralocorticoid receptor antagonists. Clinical
This 2013 review explores the dual role of the growth hormone (GH)–insulin–insulin-like growth factor-1 (IGF-1) signaling pathway in aging and cancer. In juveniles, GH promotes growth and sexual maturation; however, in adults, elevated GH/IGF-1 levels are associated with increased risks of cancer, insulin resistance, and diabetes. Studies in various organisms,
This randomized controlled trial evaluated the effects of intravenous administration of growth hormone-releasing hormone (GHRH1-29NH2) and growth hormone-releasing peptide-2 (GHRP-2), individually and combined, on growth hormone (GH) secretion in healthy adult males. GHRP-2 alone significantly increased GH secretion (AUC: 6205.1 ± 3216.9 mU/l·min) compared to GHRH alone (AUC: 2061.2 ±
